

Anti-CD19 Antibody (Obexelimab)

Introduction

Obexelimab (XmAb5871) is a humanized anti-CD19 antibody. Obexelimab can inhibit B cell activation and function by inhibiting B cell receptor (BCR)-mediated calcium flux and promoting Fcγ receptor IIb inhibitory receptor (FcγRIIb) phosphorylation, thereby inducing B cell apoptosis. Obexelimab can be used in the study of rheumatoid arthritis and systemic lupus erythematosus.

Product parameters

Alternative Names	AMG-729, XMAB 5871
Target Accession	P15391
Target	CD19
CAS number	1690307-05-1
Molecular Weight	147.24 kDa
Host	CHO
Reactivity	Human
Conjugation	Unconjugated
Form	Liquid
Concentration	See label
Buffer System	100 mM Pro 20 mM Arg pH 5.0. No preservative!
Clonality	Monoclonal
Purification	Protein A
Isotype	IgG1
Application	ELISA, FACS, Kinetics, Functional assay, Animal Model
Biological activity	-
Endotoxin	Less than 0.1 EU/ug determined by LAL method.
Sterilization	0.2 μM filtered
Reconstitution	For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
Shipping	Dry ice
Storage	-80°C
Expiration Date	2 years
Note	Please avoid freeze-thaw cycles.

Note

1. This product is for scientific research use only.



APExBIO Technology

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com

